Quality-adjusted life-years and other health indices: A comparative analysis

Clinical Therapeutics

Volumn 21, Issue 9, 1999, Pages 1605-1629

  McAlearney, Ann Scheck ^a   Schweikhart, Sharon B ^a   Pathak, Dev S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

DALY; DFLE; HALE; Health index; Health economic evaluation; QALY

Indexed keywords

ARTICLE; HEALTH STATUS; LIFE EXPECTANCY; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 0032818122     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80015-6     Document Type: Article

References (92)

1. US Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Rockville. Md; 1991:445-446.
2. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly: The effect of competing risks. Ann Intern Med. 1996;124:577-584.
3. Graham JD. An investor's look at life-saving opportunities. Risk Perspective. 1999;7:1-4.
4. Naimark D, Naglic G, Detsky AS. The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med. 1994;9:702-707.
5. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
6. Johansson PO. On the value of changes in life expectancy. J Health Econ. 1996;15:105-113.
7. Chiang CL. Competing risks in mortality analysis. Annu Rev Public Health. 1991;12:281-307.
8. Discover how to lower your age. Available at: http://www.realage.com. Accessed May 18, 1999.
9. Roizen MF, Roach K. Gains in life expectancy from medical interventions. N Engl J Med. 1998;339:1943. Letter.
10. Lee WC. Quantifying the future impact of disease on society: Life table-based measures of potential life lost. Am J Public Health. 1997;87:1456-1460.
11. Gardner JW, Sanborn JS. Years of potential life lost (YPLL)-what does it measure? Epidemiology. 1990;1:322-329.
12. Marlow AK. Potential years of life lost: What is the denominator? J Epidemiol Community Health. 1995;49:320-322.
13. Linn S, Sheps S. Disability and the years of potential productivity lost: Modifying the years of potential life lost and the investment-production-consumer model by disability level. Epidemiology. 1993;4:449-454.
14. Sanders BS. Measuring community health levels. Am J Public Health. 1964;54:1062-1070.
15. Robine JM, Mathers CD, Bucquet D. Distinguishing health expectancies and health-adjusted life expectancies from quality-adjusted life years. Am J Public Health. 1993;83:797-798.
16. Robine JM, Ritchie K. Healthy life expectancy: Evaluation of global indicator of change in population health. Br Med J. 1991;302:457-460.
17. Colvez A, Blanchet M. Potential gains in life expectancy free of disability: A tool for health planning. Int J Epidemiol. 1983;12:224-229.
18. Sullivan DF. A single index of mortality and morbidity. HSMHA Health Rep. 1971;86:347-354.
19. Ziebland S, Fitzpatrick R, Jenkinson C. Tacit models of disability underlying health status instruments. Soc Sci Med. 1993;37:69-75.
20. Valkonen T, Sihvonen AP, Lahelma E. Health expectancy by level of education in Finland. Soc Sci Med. 1997;44: 801-808.
21. Sullivan DF. Disability Components for an Index of Health. Washington, DC: US Government Printing Office; 1971. Publication 1000, Series 2, No. 42.
22. Mutafova M, van de Water HPA, Perenboom RJM, et al. Health expectancy calculations: A novel approach to studying population health in Bulgaria. Bull WHO. 1997;75:147-153.
23. Patrick DL, Bush JW, Chen MM. Methods for measuring levels of well-being for a health status index. Health Serv Res. 1973;8:229-244.
24. Bush JW, Chen M, Patrick DL. Cost-effectiveness using a health status index: Analysis of the New York State PKU screening program. In: Berg R, ed. Health Status Index. Chicago: Hospital Research and Educational Trust; 1983:172-208.
25. Chen M, Bush JW, Patrick DL. Social indicators for health planning and policy analysis. Pol Sci. 1975;6:71-89.
26. Zeckhauser R, Shepard, DS. Where now for saving lives? Law Contemp Problems. 1976;40:5-45.
27. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
28. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford University Press; 1997:138-199.
29. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:98-106.
30. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Disease, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996:61-68.
31. von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. 2nd ed. Princeton, NJ: Princeton University Press; 1953:617-632.
32. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Operations Res. 1980;28:206-224.
33. Pathak DS. QALYs in health outcomes research: Representation of real preferences or another numerical abstraction? J Res Pharm Econ. 1995;6:3-27.
34. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Mak. 1989;9:142-149.
35. Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med. 1989;28:299-308.
36. Sutherland HJ, Llewellyn-Thomas H, Boyd NF, Till JE. Attitudes toward quality of survival: The concept of maximal endurable time. Med Decis Mak. 1982;2:299-309.
37. Tsevat J, Dawson NY, Wu AW, et al, for the HELP Investigators. Health values of hospitalized patients 80 years or older. JAMA. 1998;279:371-375.
38. Carr-Hill R. Allocating resources to health care: Is the QALY (quality-adjusted life-year) a technical solution to a political program? Int J Health Serv. 1991;21:351-363.
39. Broome J. QALYs. J Public Econ. 1993;50:149-167.
40. Brock D. Quality of life measures in health care and medical ethics. In: Nussbaum MC, Sen A, eds. The Quality of Life. Oxford: Clarendon Press; 1993:95-132.
41. The World Bank. The World Development Report, 1993: Investing in Health. New York: Oxford University Press; 1993:27-35, 213-227.
42. Murray CJL. Quantifying the burden of disease: The technical basis for disability-adjusted life years. Bull WHO. 1994;72:429-445.
43. Murray CJL, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet. 1997;349:1347-1352.
44. Murray CJL, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436-1442.
45. Murray CJL, Acharya AK. Understanding DALYs. J Health Econ. 1997;16:703-730.
46. Anand S, Hanson K. Disability-adjusted life years: A critical review. J Health Econ. 1997;16:685-702.
47. Foege W. Preventive medicine and public health. JAMA. 1994;271:1704-1705.
48. Gross CP, Anderson GF, Powe NE. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999;340:1881-1887.
49. Berg RL. Weighted life expectancy as a health status index. Health Serv Res. 1973;8:153-156.
50. Torrance GW. Health status index models: A unified mathematical view. Manage Sci. 1976;22:990-1001.
51. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis. 1984;37:85-95.
52. Rosenberg MA, Fryback DG, Lawrence WF. Computing population-based estimates of health-adjusted life expectancy. Med Decis Mak. 1999;19:90-97.
53. Wilkins R, Adams OB. Health expectancies in Canada, late 1970s: Demographic, regional and social dimensions. Am J Public Health. 1983;73:1073-1080.
54. Katz S, Branch LG, Branson MH, et al. Active life expectancy. N Engl J Med. 1983;390:1218-1224.
55. Kindig DA. Purchasing Population Health: Paying for Results. Ann Arbor, Mich: University of Michigan Press; 1997:43-68.
56. Wolfson MC. Health-adjusted life expectancy. Health Rep. 1996;8:41-46.
57. Roberge R, Berthelot J-M, Wolfson M. The Health Utility Index: Measuring health differences in Ontario by socioeconomic status. Health Rep. 1995;7:25-32.
58. Barendregt JJ, Bonneux L, van der Maas PJ. Health expectancy: From population health indicator to a tool for policy making. Presented at International Network on Health Expectancy REVES 8, October 5-7, 1995.
59. Mehrez A, Gafni A. The healthy-years equivalents: How to measure them using the standard gamble approach. Med Decis Mak. 1991;11:140-146.
60. Buckingham K. A note on HYE (healthy years equivalent). J Health Econ. 1993;12:301-309.
61. Johannesson M, Pliskin JS, Weinstein MC. Are healthy-years equivalents an improvement over quality-adjusted life-years? Med Decis Mak. 1993;13:281-286.
62. Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: In pursuit of progress. Med Decis Mak. 1993;13:287-292.
63. Gafni A, Birch S, Mehrez A. Economics, health, and health economics: HYEs versus QALYs. J Health Econ. 1993;11:325-339.
64. Ried W. QALYs versus HYEs - what's right and what's wrong. A review of the controversy. J Health Econ. 1998;17:607-625.
65. Wakker P. A criticism of healthy years equivalents. Med Decis Mak. 1996;16:207-214.
66. Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assess Health Care. 1995;11:40-48.
67. Nord E. An alternative to QALYs: The saved young life equivalent (SAVE). Br Med J. 1992;305:805-807.
68. Ubel PA, Loewenstein G, Scanlon D, Kamlet M. Individual utilities are inconsistent with rationing choices: A partial explanation of why Oregon's cost-effectiveness list failed. Med Decis Mak. 1996;16:108-116.
69. Nord E. The person-trade-off approach to valuing health care programs. Med Decis Mak. 1995;15:201-208.
70. Nord E. Methods for quality adjustment of life years. Soc Sci Med. 1992;34:559-569.
71. Rosser R, Kind P. A scale of valuations of states of illness: Is there a social consensus? Int J Epidemiol. 1978;7:347-358.
72. Nord E. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy. 1993;24:227-238.
73. Erickson P, Wilson R, Shanon I. Years of Healthy Life: Statistical Note Number 7. Hyattsville, Md: National Center for Health Statistics; 1995.
74. Keeney RL, Raiffa H. Decisions with Multiple Objectives: Preferences and Value Tradeoffs. New York: John Wiley & Sons; 1976:219-546.
75. Erickson P. Evaluation of a population-based measure of quality of life: The Health and Activity Limitation Index (HALex). Qual Life Res. 1998;7:101-114.
76. Ghana Health Assessment Project Team. A quantitative method of assessing the impact of different diseases in less developed countries. Int J Epidemiol. 1981;10:73-80.
77. Barnum H. Evaluating healthy days of life gained from health projects. Soc Sci Med. 1987;24:833-841.
78. Feeny D, Torrance G, Goldsmith C, et al. A multi-attribute approach to population health status. Working Paper Series 94-5. Hamilton, Ontario, Canada: CHEPA (Centre for Health Economics and Policy Analysis); 1994.
79. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Med Care. 1989;27:S190-S204.
80. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1982;1:61-80.
81. Brooks R with the EuroQol Group. EuroQol: The current state of play. Health Policy. 1996;37:53-72.
82. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217-S232.
83. Lewis-Jones MS, Finlay AY, Owens RG. The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998;138:107-113.
84. Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: The Multi-attribute Asthma Symptom Utility Index. Chest. 1998;114:998-1007.
85. Glasziou PP, Simes RJ, Lumley T. Predicting patients' utilities from quality of life items: An improved scoring system for the UBQ-H. Qual Life Res. 1998;7:703-711.
86. Kind P, Gudex C. Measuring health status in the community: A comparison of methods. J Epidemiol Community Health. 1994;48:86-91.
87. Palmer CG, Peters ME, Green CG, et al. Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics. 1993;91:488-495.
88. Goldhirsh A, Gelber RD, Simes RJ, et al, for the Ludwig Cancer Study Group. Costs and benefits of adjuvant therapy for breast cancer: A quality adjusted survival analysis. J Clin Oncol. 1989;7:36-44.
89. Gelber RD, Cole BF, Gelber S, Goldhirsh A. The Q-TWiST method. In: Spiker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996:437-444.
90. Cole BF, Gelber RD, Anderson KM. Parametric approaches to quality-adjusted survival analysis. Biometrics. 1994;50:621-631.
91. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
92. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: An illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics. 1993;4:345-352.